Urokinase is under clinical development by Tasly Pharmaceutical Group and currently in Phase III for Acute Ischemic Stroke. According to GlobalData, Phase III drugs for Acute Ischemic Stroke have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Urokinase’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Urokinase overview
Urokinase (Pro-UK) is a proteolytic enzyme produced by the kidney and found in the urine, which acts as plasminogen activator. It is formulated as injectable solution for intravenous route of administration. It is indicated for thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Urokinase is also under development for the treatment of acute ischaemic stroke.
It was also under development for acute pulmonary embolism.
Tasly Pharmaceutical Group overview
Tasly Pharmaceutical Group (Tasly) manufactures and distributes chemical medicine, biological medicine, healthcare products, traditional Chinese medicine (TCM), functional food and other products. The company’s product line includes herbal medicine, chemical medicine, prescription drugs, pharmaceutical substances, health product, active pharmaceutical ingredients (APIs), herbal extract, tea, cosmetics, daily hygiene product series, and medical equipment. It markets products in the domestic market through its own sales force and through distributors and subsidiaries in Malaysia, Indonesia, Vietnam, South Korea, Pakistan, Thailand, Istanbul, Botswana, South Africa, Ghana, Kenya, Zambia, Nigeria, Russia, the Netherlands, and the US. Tasly is headquartered in Tianjin, China.
For a complete picture of Urokinase’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
